AbbVie Inc (ABBV) SVP Timothy J. Richmond Sells 87,040 Shares of Stock

AbbVie Inc (NYSE:ABBV) SVP Timothy J. Richmond sold 87,040 shares of the company’s stock in a transaction dated Monday, December 18th. The shares were sold at an average price of $98.45, for a total transaction of $8,569,088.00. Following the sale, the senior vice president now directly owns 113,118 shares in the company, valued at $11,136,467.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of AbbVie Inc (ABBV) opened at $97.92 on Wednesday. The firm has a market cap of $156,753.45, a P/E ratio of 18.49, a P/E/G ratio of 1.37 and a beta of 1.52. The company has a debt-to-equity ratio of 5.08, a current ratio of 1.45 and a quick ratio of 1.32. AbbVie Inc has a one year low of $59.27 and a one year high of $99.10.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 27th. The company reported $1.41 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.02. The business had revenue of $7 billion for the quarter, compared to the consensus estimate of $7 billion. AbbVie had a net margin of 24.38% and a return on equity of 153.80%. AbbVie’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period last year, the firm posted $1.21 earnings per share. equities analysts anticipate that AbbVie Inc will post 5.55 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be paid a $0.71 dividend. This is an increase from AbbVie’s previous quarterly dividend of $0.64. This represents a $2.84 dividend on an annualized basis and a yield of 2.90%. The ex-dividend date is Thursday, January 11th. AbbVie’s dividend payout ratio (DPR) is currently 62.29%.

A number of institutional investors and hedge funds have recently made changes to their positions in ABBV. Savant Capital LLC grew its position in AbbVie by 1.3% during the second quarter. Savant Capital LLC now owns 61,132 shares of the company’s stock valued at $4,433,000 after acquiring an additional 793 shares during the last quarter. Princeton Capital Management Inc. bought a new position in shares of AbbVie in the second quarter worth approximately $1,394,000. Accident Compensation Corp grew its holdings in shares of AbbVie by 24.7% in the first quarter. Accident Compensation Corp now owns 66,200 shares of the company’s stock worth $4,314,000 after purchasing an additional 13,100 shares during the last quarter. Investec Asset Management LTD grew its holdings in shares of AbbVie by 3.6% in the first quarter. Investec Asset Management LTD now owns 166,978 shares of the company’s stock worth $10,880,000 after purchasing an additional 5,801 shares during the last quarter. Finally, Palisade Asset Management LLC grew its holdings in shares of AbbVie by 17.9% in the second quarter. Palisade Asset Management LLC now owns 68,311 shares of the company’s stock worth $4,953,000 after purchasing an additional 10,381 shares during the last quarter. 69.18% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently issued reports on ABBV shares. Zacks Investment Research raised shares of AbbVie from a “hold” rating to a “buy” rating and set a $102.00 price target on the stock in a report on Tuesday, October 17th. BidaskClub downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 25th. Goldman Sachs Group reissued a “buy” rating and issued a $100.00 price target (up from $85.00) on shares of AbbVie in a report on Friday, September 8th. Deutsche Bank increased their price target on shares of AbbVie to $88.00 and gave the stock a “hold” rating in a report on Thursday, September 28th. Finally, Jefferies Group reissued a “buy” rating and issued a $107.00 price target (up from $94.00) on shares of AbbVie in a report on Friday, September 15th. Seven investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $97.96.

COPYRIGHT VIOLATION WARNING: “AbbVie Inc (ABBV) SVP Timothy J. Richmond Sells 87,040 Shares of Stock” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://sportsperspectives.com/2017/12/20/abbvie-inc-abbv-svp-timothy-j-richmond-sells-87040-shares-of-stock.html.

About AbbVie

AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.

Insider Buying and Selling by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply